Dong Wha Pharmaceutical Co. Ltd.

18 clinical trials · Sponsor

Record	Firm	Date
DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes (NCT06875193)	Dong Wha Pharmaceutical Co. Ltd.	2024-05-28
This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition. (NCT05823883)	Dong Wha Pharmaceutical Co. Ltd.	2023-06-01
This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition. (NCT05823870)	Dong Wha Pharmaceutical Co. Ltd.	2023-02-24
A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition (NCT05874180)	Dong Wha Pharmaceutical Co. Ltd.	2023-01-09
A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers (NCT05874167)	Dong Wha Pharmaceutical Co. Ltd.	2022-08-08
A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers (NCT05403281)	Dong Wha Pharmaceutical Co. Ltd.	2021-11-05
A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety After 6 Months of Administration of Atostazet to Hypercholesterolemic Patients 65 Years of Age or Older (NCT07489183)	Dong Wha Pharmaceutical Co. Ltd.	2021-08-23

Every clearance here is in the API, with alerts when new ones post.